{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:59:22Z","timestamp":1795211962272,"version":"4.10.3"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41584-024-01163-z","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:02:24Z","timestamp":1727852544000},"page":"712-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Recent advances in the diagnosis and management of neuropsychiatric lupus"],"prefix":"10.1038","volume":"20","author":[{"given":"Alexandra C.","family":"Legge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Hanly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X","volume":"45","author":"H Ainiala","year":"2001","unstructured":"Ainiala, H. et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 45, 419\u2013423 (2001).","journal-title":"Arthritis Rheum."},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","volume":"41","author":"A Unterman","year":"2011","unstructured":"Unterman, A. et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin. Arthritis Rheum. 41, 1\u201311 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"1163_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055843","volume":"8","author":"EI Kampylafka","year":"2013","unstructured":"Kampylafka, E. I. et al. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS ONE 8, e55843 (2013).","journal-title":"PLoS ONE"},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/ard.2010.130476","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias, G. K. et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 69, 2074\u20132082 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","volume":"42","author":"ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature.","year":"1999","unstructured":"ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42, 599\u2013608 (1999).","journal-title":"Arthritis Rheum."},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/art.22305","volume":"56","author":"JG Hanly","year":"2007","unstructured":"Hanly, J. G. et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 56, 265\u2013273 (2007).","journal-title":"Arthritis Rheum."},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/art.23566","volume":"59","author":"JG Hanly","year":"2008","unstructured":"Hanly, J. G. et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 59, 721\u2013729 (2008).","journal-title":"Arthritis Rheum."},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/rheumatology\/keu384","volume":"54","author":"A Bortoluzzi","year":"2015","unstructured":"Bortoluzzi, A. et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology 54, 891\u2013898 (2015).","journal-title":"Rheumatology"},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/rheumatology\/kex019","volume":"56","author":"C Magro-Checa","year":"2017","unstructured":"Magro-Checa, C. et al. Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. Rheumatology 56, 1676\u20131683 (2017).","journal-title":"Rheumatology"},{"key":"1163_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015546","volume":"7","author":"A Bortoluzzi","year":"2017","unstructured":"Bortoluzzi, A. et al. Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. BMJ Open\u00a07, e015546 (2017).","journal-title":"BMJ Open"},{"key":"1163_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000629","volume":"9","author":"RC Monahan","year":"2022","unstructured":"Monahan, R. C. et al. To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus. Lupus Sci. Med. 9, e000629 (2022).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/art.41876","volume":"73","author":"JG Hanly","year":"2021","unstructured":"Hanly, J. G. et al. Neuropsychiatric events in systemic lupus erythematosus: predictors of occurrence and resolution in a longitudinal analysis of an international inception cohort. Arthritis Rheumatol. 73, 2293\u20132302 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/ard.2008.106351","volume":"69","author":"JG Hanly","year":"2010","unstructured":"Hanly, J. G. et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 529\u2013535 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/ard.2007.077594","volume":"67","author":"RM Andrade","year":"2008","unstructured":"Andrade, R. M. et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann. Rheum. Dis. 67, 829\u2013834 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/art.23098","volume":"57","author":"P Tomietto","year":"2007","unstructured":"Tomietto, P. et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 57, 1461\u20131472 (2007).","journal-title":"Arthritis Rheum."},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/rheumatology\/keh384","volume":"43","author":"J Mikdashi","year":"2004","unstructured":"Mikdashi, J. & Handwerger, B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 43, 1555\u20131560 (2004).","journal-title":"Rheumatology"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1212\/01.WNL.0000165959.98370.D5","volume":"64","author":"J Mikdashi","year":"2005","unstructured":"Mikdashi, J., Krumholz, A. & Handwerger, B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64, 2102\u20132107 (2005).","journal-title":"Neurology"},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/ard.62.9.859","volume":"62","author":"S Bujan","year":"2003","unstructured":"Bujan, S. et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann. Rheum. Dis. 62, 859\u2013865 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1212\/01.WNL.0000144178.32208.4F","volume":"63","author":"S Appenzeller","year":"2004","unstructured":"Appenzeller, S., Cendes, F. & Costallat, L. T. Epileptic seizures in systemic lupus erythematosus. Neurology 63, 1808\u20131812 (2004).","journal-title":"Neurology"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/art.40764","volume":"71","author":"JG Hanly","year":"2019","unstructured":"Hanly, J. G. et al. Psychosis in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol. 71, 281\u2013289 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","volume":"71","author":"JG Hanly","year":"2012","unstructured":"Hanly, J. G. et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann. Rheum. Dis. 71, 1502\u20131509 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaut.2018.03.001","volume":"91","author":"S Gelb","year":"2018","unstructured":"Gelb, S., Stock, A. D., Anzi, S., Putterman, C. & Ben-Zvi, A. Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J. Autoimmun. 91, 34\u201344 (2018).","journal-title":"J. Autoimmun."},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/ard-2022-223506","volume":"82","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos, D. et al. Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus. Ann. Rheum. Dis. 82, 646\u2013657 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/ard-2022-222566","volume":"81","author":"N Abe","year":"2022","unstructured":"Abe, N. et al. Pathogenic neuropsychiatric effect of stress-induced microglial interleukin 12\/23 axis in systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1564\u20131575 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/art.42352","volume":"75","author":"K Karino","year":"2023","unstructured":"Karino, K. et al. Inhibitor of NF-\u03baB kinase subunit \u03b5 contributes to neuropsychiatric manifestations in lupus-prone mice through microglial activation. Arthritis Rheumatol. 75, 411\u2013423 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.42252","volume":"74","author":"E Moore","year":"2022","unstructured":"Moore, E., Huang, M. W., Reynolds, C. A., Macian, F. & Putterman, C. Choroid plexus-infiltrating T cells as drivers of murine neuropsychiatric lupus. Arthritis Rheumatol. 74, 1796\u20131807 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/BOR.0000000000000682","volume":"32","author":"E Moore","year":"2020","unstructured":"Moore, E., Huang, M. W. & Putterman, C. Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. Curr. Opin. Rheumatol. 32, 152\u2013158 (2020).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"117419","DOI":"10.1016\/j.jns.2021.117419","volume":"424","author":"JG Hanly","year":"2021","unstructured":"Hanly, J. G. & Inanc, M. The neurology of lupus. J. Neurol. Sci. 424, 117419 (2021).","journal-title":"J. Neurol. Sci."},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41584-018-0156-8","volume":"15","author":"N Schwartz","year":"2019","unstructured":"Schwartz, N., Stock, A. D. & Putterman, C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat. Rev. Rheumatol. 15, 137\u2013152 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1163_CR30","first-page":"985","volume":"30","author":"G Sanna","year":"2003","unstructured":"Sanna, G. et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30, 985\u2013992 (2003).","journal-title":"J. Rheumatol."},{"key":"1163_CR31","first-page":"622","volume":"32","author":"MY Mok","year":"2005","unstructured":"Mok, M. Y. et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 32, 622\u2013628 (2005).","journal-title":"J. Rheumatol."},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.autrev.2015.10.003","volume":"15","author":"RC Ho","year":"2016","unstructured":"Ho, R. C. et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun. Rev. 15, 124\u2013138 (2016).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.23509","volume":"70","author":"JG Hanly","year":"2018","unstructured":"Hanly, J. G. et al. Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Care Res. 70, 1478\u20131487 (2018).","journal-title":"Arthritis Care Res."},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.thromres.2018.07.005","volume":"169","author":"M Green","year":"2018","unstructured":"Green, M. et al. Non-genetic and genetic risk factors for adult cerebral venous thrombosis. Thromb. Res. 169, 15\u201322 (2018).","journal-title":"Thromb. Res."},{"key":"1163_CR35","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/1529-0131(199904)42:4<728::AID-ANR16>3.0.CO;2-O","volume":"42","author":"JG Hanly","year":"1999","unstructured":"Hanly, J. G., Hong, C., Smith, S. & Fisk, J. D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 42, 728\u2013734 (1999).","journal-title":"Arthritis Rheum."},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00109-003-0423-1","volume":"81","author":"M Mahler","year":"2003","unstructured":"Mahler, M. et al. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J. Mol. Med. 81, 194\u2013204 (2003).","journal-title":"J. Mol. Med."},{"key":"1163_CR37","doi-asserted-by":"publisher","first-page":"102463","DOI":"10.1016\/j.autrev.2020.102463","volume":"19","author":"MY Choi","year":"2020","unstructured":"Choi, M. Y., FitzPatrick, R. D., Buhler, K., Mahler, M. & Fritzler, M. J. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun. Rev. 19, 102463 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001005","volume":"10","author":"E Chessa","year":"2023","unstructured":"Chessa, E. et al. Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study. Lupus Sci. Med. 10, e001005 (2023).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR39","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/rheumatology\/41.12.1357","volume":"41","author":"R Gerli","year":"2002","unstructured":"Gerli, R. et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology 41, 1357\u20131366 (2002).","journal-title":"Rheumatology"},{"key":"1163_CR40","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1093\/rheumatology\/keab160","volume":"60","author":"E Abrol","year":"2021","unstructured":"Abrol, E. et al. Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre. Rheumatology 60, 5620\u20135629 (2021).","journal-title":"Rheumatology"},{"key":"1163_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/s10165-010-0354-y","volume":"21","author":"T Nagai","year":"2011","unstructured":"Nagai, T., Yanagida, T. & Hirohata, S. Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes. Mod. Rheumatol. 21, 57\u201362 (2011).","journal-title":"Mod. Rheumatol."},{"key":"1163_CR42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/art.38900","volume":"67","author":"M Bravo-Zehnder","year":"2015","unstructured":"Bravo-Zehnder, M. et al. Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol. 67, 204\u2013214 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR43","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/art.22419","volume":"56","author":"A Katzav","year":"2007","unstructured":"Katzav, A. et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 56, 938\u2013948 (2007).","journal-title":"Arthritis Rheum."},{"key":"1163_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","volume":"1366","author":"SJ Pittock","year":"2016","unstructured":"Pittock, S. J. & Lucchinetti, C. F. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann. N. Y. Acad. Sci. 1366, 20\u201339 (2016).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1163_CR45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters, P. J. et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78, 665\u2013671 (2012).","journal-title":"Neurology"},{"key":"1163_CR46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao, Y. et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81, 1197\u20131204 (2013).","journal-title":"Neurology"},{"key":"1163_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock, S. J. et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch. Neurol. 65, 78\u201383 (2008).","journal-title":"Arch. Neurol."},{"key":"1163_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.40356","volume":"70","author":"S Mader","year":"2018","unstructured":"Mader, S. et al. Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets? Arthritis Rheumatol. 70, 277\u2013286 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2015.10.007","volume":"289","author":"H Alexopoulos","year":"2015","unstructured":"Alexopoulos, H. et al. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. J. Neuroimmunol. 289, 8\u201311 (2015).","journal-title":"J. Neuroimmunol."},{"key":"1163_CR50","doi-asserted-by":"publisher","first-page":"18569","DOI":"10.1073\/pnas.1006980107","volume":"107","author":"TW Faust","year":"2010","unstructured":"Faust, T. W. et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl Acad. Sci. USA 107, 18569\u201318574 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/nm1101-1189","volume":"7","author":"LA DeGiorgio","year":"2001","unstructured":"DeGiorgio, L. A. et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189\u20131193 (2001).","journal-title":"Nat. Med."},{"key":"1163_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15224-w","volume":"11","author":"K Chan","year":"2020","unstructured":"Chan, K. et al. Lupus autoantibodies act as positive allosteric modulators at GluN2A-containing NMDA receptors and impair spatial memory. Nat. Commun. 11, 1403 (2020).","journal-title":"Nat. Commun."},{"key":"1163_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.autrev.2016.12.002","volume":"16","author":"SH Tay","year":"2017","unstructured":"Tay, S. H., Fairhurst, A. M. & Mak, A. Clinical utility of circulating anti-N-methyl-d-aspartate receptor subunits NR2A\/B antibody for the diagnosis of neuropsychiatric syndromes in systemic lupus erythematosus and Sjogren\u2019s syndrome: an updated meta-analysis. Autoimmun. Rev. 16, 114\u2013122 (2017).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1468-1331.2004.00976.x","volume":"12","author":"R Omdal","year":"2005","unstructured":"Omdal, R. et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12, 392\u2013398 (2005).","journal-title":"Eur. J. Neurol."},{"key":"1163_CR55","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/art.22030","volume":"54","author":"MJ Harrison","year":"2006","unstructured":"Harrison, M. J., Ravdin, L. D. & Lockshin, M. D. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum. 54, 2515\u20132522 (2006).","journal-title":"Arthritis Rheum."},{"key":"1163_CR56","first-page":"1553","volume":"33","author":"JG Hanly","year":"2006","unstructured":"Hanly, J. G., Robichaud, J. & Fisk, J. D. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol. 33, 1553\u20131558 (2006).","journal-title":"J. Rheumatol."},{"key":"1163_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2004.07.011","volume":"21","author":"C Kowal","year":"2004","unstructured":"Kowal, C. et al. Cognition and immunity; antibody impairs memory. Immunity 21, 179\u2013188 (2004).","journal-title":"Immunity"},{"key":"1163_CR58","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1073\/pnas.0510055103","volume":"103","author":"PT Huerta","year":"2006","unstructured":"Huerta, P. T., Kowal, C., DeGiorgio, L. A., Volpe, B. T. & Diamond, B. Immunity and behavior: antibodies alter emotion. Proc. Natl Acad. Sci. USA 103, 678\u2013683 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR59","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/art.21547","volume":"54","author":"T Yoshio","year":"2006","unstructured":"Yoshio, T., Onda, K., Nara, H. & Minota, S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 54, 675\u2013678 (2006).","journal-title":"Arthritis Rheum."},{"key":"1163_CR60","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/art.23399","volume":"58","author":"Y Arinuma","year":"2008","unstructured":"Arinuma, Y., Yanagida, T. & Hirohata, S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 58, 1130\u20131135 (2008).","journal-title":"Arthritis Rheum."},{"key":"1163_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clim.2017.11.006","volume":"193","author":"K Ichinose","year":"2018","unstructured":"Ichinose, K. et al. Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus. Clin. Immunol. 193, 123\u2013130 (2018).","journal-title":"Clin. Immunol."},{"key":"1163_CR62","doi-asserted-by":"publisher","first-page":"108980","DOI":"10.1016\/j.clim.2022.108980","volume":"237","author":"TTT Hoang","year":"2022","unstructured":"Hoang, T. T. T. et al. Measurement of anti-suprabasin antibodies, multiple cytokines and chemokines as potential predictive biomarkers for neuropsychiatric systemic lupus erythematosus. Clin. Immunol. 237, 108980 (2022).","journal-title":"Clin. Immunol."},{"key":"1163_CR63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/0961203319828818","volume":"28","author":"K Kitagori","year":"2019","unstructured":"Kitagori, K. et al. Utility of osteopontin in cerebrospinal fluid as a diagnostic marker for neuropsychiatric systemic lupus erythematosus. Lupus 28, 414\u2013422 (2019).","journal-title":"Lupus"},{"key":"1163_CR64","doi-asserted-by":"publisher","first-page":"175628642110514","DOI":"10.1177\/17562864211051497","volume":"14","author":"S Engel","year":"2021","unstructured":"Engel, S. et al. Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus. Ther. Adv. Neurol. Disord. 14, 17562864211051497 (2021).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1163_CR65","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00415-020-10290-y","volume":"268","author":"AB Tjensvoll","year":"2021","unstructured":"Tjensvoll, A. B. et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sjogren\u2019s syndrome. J. Neurol. 268, 1385\u20131394 (2021).","journal-title":"J. Neurol."},{"key":"1163_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02998-3","volume":"22","author":"KA Zervides","year":"2022","unstructured":"Zervides, K. A. et al. Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. BMC Neurol. 22, 467 (2022).","journal-title":"BMC Neurol."},{"key":"1163_CR67","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.autrev.2014.11.001","volume":"14","author":"N Sarbu","year":"2015","unstructured":"Sarbu, N. et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun. Rev. 14, 153\u2013159 (2015).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR68","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1177\/0961203317691373","volume":"26","author":"M Postal","year":"2017","unstructured":"Postal, M., Lapa, A. T., Reis, F., Rittner, L. & Appenzeller, S. Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: current state of the art and novel approaches. Lupus 26, 517\u2013521 (2017).","journal-title":"Lupus"},{"key":"1163_CR69","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1177\/0961203315593819","volume":"24","author":"M Barraclough","year":"2015","unstructured":"Barraclough, M., Elliott, R., McKie, S., Parker, B. & Bruce, I. N. Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus. Lupus 24, 1239\u20131247 (2015).","journal-title":"Lupus"},{"key":"1163_CR70","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0961203318763533","volume":"27","author":"B Cannerfelt","year":"2018","unstructured":"Cannerfelt, B. et al. White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus 27, 1140\u20131149 (2018).","journal-title":"Lupus"},{"key":"1163_CR71","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/cne.24656","volume":"527","author":"J Nystedt","year":"2019","unstructured":"Nystedt, J. et al. Functional connectivity changes in core resting state networks are associated with cognitive performance in systemic lupus erythematosus. J. Comp. Neurol. 527, 1837\u20131856 (2019).","journal-title":"J. Comp. Neurol."},{"key":"1163_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/ene.14041","volume":"27","author":"P Preziosa","year":"2020","unstructured":"Preziosa, P. et al. Structural and functional brain connectomes in patients with systemic lupus erythematosus. Eur. J. Neurol. 27, 113-e2 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1163_CR73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00296-002-0224-9","volume":"22","author":"WS Huang","year":"2002","unstructured":"Huang, W. S., Chiu, P. Y., Tsai, C. H., Kao, A. & Lee, C. C. Objective evidence of abnormal regional cerebral blood flow in patients with systemic lupus erythematosus on Tc-99m ECD brain SPECT. Rheumatol. Int. 22, 178\u2013181 (2002).","journal-title":"Rheumatol. Int."},{"key":"1163_CR74","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/art.23308","volume":"59","author":"CB Driver","year":"2008","unstructured":"Driver, C. B. et al. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 59, 332\u2013337 (2008).","journal-title":"Arthritis Rheum."},{"key":"1163_CR75","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J","volume":"42","author":"WL Sibbitt Jr","year":"1999","unstructured":"Sibbitt, W. L. Jr, Sibbitt, R. R. & Brooks, W. M. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 42, 2026\u20132038 (1999).","journal-title":"Arthritis Rheum."},{"key":"1163_CR76","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/hbm.24837","volume":"41","author":"Z Zhuo","year":"2020","unstructured":"Zhuo, Z. et al. Different patterns of cerebral perfusion in SLE patients with and without neuropsychiatric manifestations. Hum. Brain Mapp. 41, 755\u2013766 (2020).","journal-title":"Hum. Brain Mapp."},{"key":"1163_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/0961203313511556","volume":"23","author":"A Zimny","year":"2014","unstructured":"Zimny, A. et al. In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. Lupus 23, 10\u201319 (2014).","journal-title":"Lupus"},{"key":"1163_CR78","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/0961203307084723","volume":"16","author":"S Appenzeller","year":"2007","unstructured":"Appenzeller, S., Li, L. M., Costallat, L. T. & Cendes, F. Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus 16, 963\u2013971 (2007).","journal-title":"Lupus"},{"key":"1163_CR79","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.autrev.2017.11.008","volume":"17","author":"BL Costallat","year":"2018","unstructured":"Costallat, B. L. et al. Brain diffusion tensor MRI in systematic lupus erythematosus: a systematic review. Autoimmun. Rev. 17, 36\u201343 (2018).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR80","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/1971400918793601","volume":"31","author":"DG Correa","year":"2018","unstructured":"Correa, D. G. et al. White-matter integrity in patients with systemic lupus erythematosus and memory deficits. Neuroradiol. J. 31, 587\u2013595 (2018).","journal-title":"Neuroradiol. J."},{"key":"1163_CR81","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1177\/0961203318793215","volume":"27","author":"E Kozora","year":"2018","unstructured":"Kozora, E. et al. Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus. Lupus 27, 1810\u20131818 (2018).","journal-title":"Lupus"},{"key":"1163_CR82","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/1529-0131(200001)43:1<48::AID-ANR7>3.0.CO;2-H","volume":"43","author":"GP Bosma","year":"2000","unstructured":"Bosma, G. P., Rood, M. J., Zwinderman, A. H., Huizinga, T. W. & van Buchem, M. A. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum. 43, 48\u201354 (2000).","journal-title":"Arthritis Rheum."},{"key":"1163_CR83","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.10574","volume":"46","author":"GP Bosma","year":"2002","unstructured":"Bosma, G. P. et al. Association of global brain damage and clinical functioning in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 46, 665\u20132672 (2002).","journal-title":"Arthritis Rheum."},{"key":"1163_CR84","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nicl.2015.05.002","volume":"8","author":"E Ercan","year":"2015","unstructured":"Ercan, E. et al. A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. Neuroimage Clin. 8, 337\u2013344 (2015).","journal-title":"Neuroimage Clin."},{"key":"1163_CR85","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.39653","volume":"68","author":"C Magro-Checa","year":"2016","unstructured":"Magro-Checa, C. et al. Changes in white matter microstructure suggest an inflammatory origin of neuropsychiatric systemic lupus erythematosus. Arthritis Rheumatol. 68, 1945\u20131954 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1749-6632.2011.06076.x","volume":"1228","author":"R Curiel","year":"2011","unstructured":"Curiel, R., Akin, E. A., Beaulieu, G., DePalma, L. & Hashefi, M. PET\/CT imaging in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1228, 71\u201380 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1163_CR87","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124002","volume":"4","author":"M Mackay","year":"2019","unstructured":"Mackay, M. et al. Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. JCI Insight 4, e124002 (2019).","journal-title":"JCI Insight"},{"key":"1163_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000327","volume":"6","author":"E Ploran","year":"2019","unstructured":"Ploran, E. et al. Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. Lupus Sci. Med. 6, e000327 (2019).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074530","volume":"8","author":"J Hou","year":"2013","unstructured":"Hou, J. et al. Abnormalities of frontal-parietal resting-state functional connectivity are related to disease activity in patients with systemic lupus erythematosus. PLoS ONE 8, e74530 (2013).","journal-title":"PLoS ONE"},{"key":"1163_CR90","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/hbm.21158","volume":"32","author":"Y Lin","year":"2011","unstructured":"Lin, Y. et al. Localization of cerebral functional deficits in patients with non-neuropsychiatric systemic lupus erythematosus. Hum. Brain. Mapp. 32, 1847\u20131855 (2011).","journal-title":"Hum. Brain. Mapp."},{"key":"1163_CR91","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41380-020-00907-z","volume":"26","author":"R Bonacchi","year":"2021","unstructured":"Bonacchi, R. et al. Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. Mol. Psychiatry 26, 3634\u20133645 (2021).","journal-title":"Mol. Psychiatry"},{"key":"1163_CR92","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00234-018-2138-6","volume":"61","author":"H Yu","year":"2019","unstructured":"Yu, H. et al. Abnormal amplitude of low frequency fluctuation and functional connectivity in non-neuropsychiatric systemic lupus erythematosus: a resting-state fMRI study. Neuroradiology 61, 331\u2013340 (2019).","journal-title":"Neuroradiology"},{"key":"1163_CR93","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3389\/fpsyt.2018.00677","volume":"9","author":"S Liu","year":"2018","unstructured":"Liu, S. et al. A conscious resting state fMRI study in SLE patients without major neuropsychiatric manifestations. Front. Psychiatry 9, 677 (2018).","journal-title":"Front. Psychiatry"},{"key":"1163_CR94","doi-asserted-by":"publisher","first-page":"SI39","DOI":"10.1093\/rheumatology\/keab734","volume":"61","author":"M Barraclough","year":"2022","unstructured":"Barraclough, M., McKie, S., Parker, B., Elliott, R. & Bruce, I. N. The effects of disease activity, inflammation, depression and cognitive fatigue on resting state fMRI in systemic lupus erythematosus. Rheumatology 61, SI39\u2013SI47 (2022).","journal-title":"Rheumatology"},{"key":"1163_CR95","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/rheumatology\/keac343","volume":"62","author":"JG Hanly","year":"2023","unstructured":"Hanly, J. G. et al. Resting state functional connectivity in SLE patients and association with cognitive impairment and blood-brain barrier permeability. Rheumatology 62, 685\u2013695 (2023).","journal-title":"Rheumatology"},{"key":"1163_CR96","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/annrheumdis-2018-214677","volume":"78","author":"M Barraclough","year":"2019","unstructured":"Barraclough, M. et al. Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Ann. Rheum. Dis. 78, 934\u2013940 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR97","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/jmri.26006","volume":"48","author":"BB Wu","year":"2018","unstructured":"Wu, B. B. et al. Impaired decision-making and functional neuronal network activity in systemic lupus erythematosus. J. Magn. Reson. Imaging 48, 1508\u20131517 (2018).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1163_CR98","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/annrheumdis-2020-218004","volume":"79","author":"L Kamintsky","year":"2020","unstructured":"Kamintsky, L. et al. Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. Ann. Rheum. Dis. 79, 1580\u20131587 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR99","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/acr.22923","volume":"69","author":"G Gulati","year":"2017","unstructured":"Gulati, G. et al. Altered blood-brain barrier permeability in patients with systemic lupus erythematosus: a novel imaging approach. Arthritis Care Res. 69, 299\u2013305 (2017).","journal-title":"Arthritis Care Res."},{"key":"1163_CR100","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/rheumatology\/kead221","volume":"63","author":"SH Tay","year":"2023","unstructured":"Tay, S. H. et al. Combining multimodal magnetic resonance brain imaging and machine learning to unravel neurocognitive function in non-neuropsychiatric systemic lupus erythematosus. Rheumatology 63, 414\u2013422 (2023).","journal-title":"Rheumatology"},{"key":"1163_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semarthrit.2020.12.004","volume":"51","author":"DA Papachristos","year":"2021","unstructured":"Papachristos, D. A., Oon, S., Hanly, J. G. & Nikpour, M. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. 51, 49\u201371 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1163_CR102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s42358-019-0047-y","volume":"59","author":"CTM Conceicao","year":"2019","unstructured":"Conceicao, C. T. M., Meinao, I. M., Bombana, J. A. & Sato, E. I. Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial. Adv. Rheumatol. 59, 4 (2019).","journal-title":"Adv. Rheumatol."},{"key":"1163_CR103","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/art.39111","volume":"67","author":"JG Hanly","year":"2015","unstructured":"Hanly, J. G. et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol. 67, 1837\u20131847 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR104","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/0961203316674820","volume":"26","author":"N Sarbu","year":"2017","unstructured":"Sarbu, N. et al. Advanced MRI techniques: biomarkers in neuropsychiatric lupus. Lupus 26, 510\u2013516 (2017).","journal-title":"Lupus"},{"key":"1163_CR105","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.27289","volume":"62","author":"H Jung","year":"2010","unstructured":"Jung, H. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62, 863\u2013868 (2010).","journal-title":"Arthritis Rheum."},{"key":"1163_CR106","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296\u20131304 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR107","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","volume":"13","author":"L Arnaud","year":"2014","unstructured":"Arnaud, L. et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun. Rev. 13, 281\u2013291 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR108","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","volume":"14","author":"L Arnaud","year":"2015","unstructured":"Arnaud, L. et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 14, 192\u2013200 (2015).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR109","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1002\/art.22663","volume":"56","author":"D Erkan","year":"2007","unstructured":"Erkan, D. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56, 2382\u20132391 (2007).","journal-title":"Arthritis Rheum."},{"key":"1163_CR110","first-page":"CD012534","volume":"7","author":"MM Bala","year":"2018","unstructured":"Bala, M. M. et al. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst. Rev. 7, CD012534 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1163_CR111","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1161\/STROKEAHA.122.039579","volume":"53","author":"S Yaghi","year":"2022","unstructured":"Yaghi, S. et al. Direct oral anticoagulants versus vitamin K antagonists in cerebral venous thrombosis: a systematic review and meta-analysis. Stroke 53, 3014\u20133024 (2022).","journal-title":"Stroke"},{"key":"1163_CR112","doi-asserted-by":"publisher","first-page":"107223","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107223","volume":"32","author":"N Simaan","year":"2023","unstructured":"Simaan, N. et al. Factors influencing real-life use of direct oral anticoagulants in patients with cerebral sinus and venous thrombosis. J. Stroke Cerebrovasc. Dis. 32, 107223 (2023).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"1163_CR113","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo, V. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132, 1365\u20131371 (2018).","journal-title":"Blood"},{"key":"1163_CR114","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","volume":"17","author":"V Dufrost","year":"2018","unstructured":"Dufrost, V. et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun. Rev. 17, 1011\u20131021 (2018).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR115","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-0291","volume":"171","author":"J Ordi-Ros","year":"2019","unstructured":"Ordi-Ros, J. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann. Intern. Med. 171, 685\u2013694 (2019).","journal-title":"Ann. Intern. Med."},{"key":"1163_CR116","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1056\/NEJMoa035241","volume":"349","author":"MA Crowther","year":"2003","unstructured":"Crowther, M. A. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349, 1133\u20131138 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR117","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","volume":"3","author":"G Finazzi","year":"2005","unstructured":"Finazzi, G. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3, 848\u2013853 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"1163_CR118","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/art.23109","volume":"57","author":"G Ruiz-Irastorza","year":"2007","unstructured":"Ruiz-Irastorza, G., Hunt, B. J. & Khamashta, M. A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 57, 1487\u20131495 (2007).","journal-title":"Arthritis Rheum."},{"key":"1163_CR119","first-page":"15","volume":"7","author":"H Okuma","year":"2009","unstructured":"Okuma, H., Kitagawa, Y., Yasuda, T., Tokuoka, K. & Takagi, S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int. J. Med. Sci. 7, 15\u201318 (2009).","journal-title":"Int. J. Med. Sci."},{"key":"1163_CR120","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos, G. C. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. 81, 768\u2013779 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR121","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/annrheumdis-2019-216150","volume":"79","author":"JG Hanly","year":"2020","unstructured":"Hanly, J. G. et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann. Rheum. Dis. 79, 356\u2013362 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR122","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/0961203315622821","volume":"25","author":"A Fanouriakis","year":"2016","unstructured":"Fanouriakis, A. et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus 25, 627\u2013636 (2016).","journal-title":"Lupus"},{"key":"1163_CR123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0002-9343(03)00135-9","volume":"115","author":"CC Mok","year":"2003","unstructured":"Mok, C. C., Lau, C. S. & Wong, R. W. S. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am. J. Med. 115, 59\u201362 (2003).","journal-title":"Am. J. Med."},{"key":"1163_CR124","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/art.1780370907","volume":"37","author":"SD Denburg","year":"1994","unstructured":"Denburg, S. D., Carbotte, R. M. & Denburg, J. A. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 37, 1311\u20131320 (1994).","journal-title":"Arthritis Rheum."},{"key":"1163_CR125","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2004.025528","volume":"64","author":"L Barile-Fabris","year":"2005","unstructured":"Barile-Fabris, L. et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 620\u2013625 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR126","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-023-03030-w","volume":"25","author":"Y Nie","year":"2023","unstructured":"Nie, Y. et al. The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE. Arthritis Res. Ther. 25, 50 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"1163_CR127","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1191\/0961203303lu450xx","volume":"12","author":"K Saito","year":"2003","unstructured":"Saito, K. et al. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 12, 798\u2013800 (2003).","journal-title":"Lupus"},{"key":"1163_CR128","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2007","unstructured":"Tokunaga, M. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66, 470\u2013475 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR129","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","volume":"83","author":"RC Dale","year":"2014","unstructured":"Dale, R. C. et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 83, 142\u2013150 (2014).","journal-title":"Neurology"},{"key":"1163_CR130","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","volume":"71","author":"S Manzi","year":"2012","unstructured":"Manzi, S. et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann. Rheum. Dis. 71, 1833\u20131838 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR131","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/rheumatology\/kead249","volume":"63","author":"L Palazzo","year":"2023","unstructured":"Palazzo, L., Lindblom, J., Cetrez, N., Ala, H. & Parodis, I. Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab. Rheumatology 63, 798\u2013808 (2023).","journal-title":"Rheumatology"},{"key":"1163_CR132","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR133","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie, R. et al. Anifrolumab, an anti-Interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376\u2013386 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR134","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.semarthrit.2018.02.007","volume":"48","author":"HA Rayes","year":"2018","unstructured":"Rayes, H. A. et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin. Arthritis Rheum. 48, 240\u2013255 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"1163_CR135","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-L","volume":"42","author":"S Menon","year":"1999","unstructured":"Menon, S. et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 42, 735\u2013741 (1999).","journal-title":"Arthritis Rheum."},{"key":"1163_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196103","volume":"13","author":"F Ceccarelli","year":"2018","unstructured":"Ceccarelli, F. et al. Cognitive dysfunction improves in systemic lupus erythematosus: results of a 10 years prospective study. PLoS ONE 13, e0196103 (2018).","journal-title":"PLoS ONE"},{"key":"1163_CR137","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/09612033221098534","volume":"31","author":"E Kozora","year":"2022","unstructured":"Kozora, E., Zell, J. L., Baraghoshi, D., Smith, R. M. & Strand, M. Improved executive function in patients with systemic lupus erythematosus following interactive digital training. Lupus 31, 910\u2013920 (2022).","journal-title":"Lupus"},{"key":"1163_CR138","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/acr.21566","volume":"64","author":"LJ Julian","year":"2012","unstructured":"Julian, L. J. et al. Validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 64, 448\u2013454 (2012).","journal-title":"Arthritis Care Res."},{"key":"1163_CR139","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3899\/jrheum.111504","volume":"39","author":"JG Hanly","year":"2012","unstructured":"Hanly, J. G., Su, L., Omisade, A., Farewell, V. T. & Fisk, J. D. Screening for cognitive impairment in systemic lupus erythematosus. J. Rheumatol. 39, 1371\u20131377 (2012).","journal-title":"J. Rheumatol."},{"key":"1163_CR140","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/13854046.2017.1368716","volume":"32","author":"AS Vincent","year":"2018","unstructured":"Vincent, A. S., Roebuck-Spencer, T. M., Fuenzalida, E. & Gilliland, K. Test-retest reliability and practice effects for the ANAM General Neuropsychological Screening battery. Clin. Neuropsychol. 32, 479\u2013494 (2018).","journal-title":"Clin. Neuropsychol."},{"key":"1163_CR141","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/acr.24096","volume":"72","author":"OE Tayer-Shifman","year":"2020","unstructured":"Tayer-Shifman, O. E. et al. Validity evidence for the use of Automated Neuropsychologic Assessment Metrics as a screening tool for cognitive impairment in systemic lupus erythematosus. Arthritis Care Res. 72, 1809\u20131819 (2020).","journal-title":"Arthritis Care Res."},{"key":"1163_CR142","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/09612033211062530","volume":"31","author":"K Yuen","year":"2022","unstructured":"Yuen, K. et al. Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus. Lupus 31, 45\u201354 (2022).","journal-title":"Lupus"},{"key":"1163_CR143","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3899\/jrheum.161125","volume":"44","author":"SG Nantes","year":"2017","unstructured":"Nantes, S. G., Su, J., Dhaliwal, A., Colosimo, K. & Touma, Z. Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J. Rheumatol. 44, 1583\u20131589 (2017).","journal-title":"J. Rheumatol."},{"key":"1163_CR144","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0961203318815299","volume":"28","author":"NE Chalhoub","year":"2019","unstructured":"Chalhoub, N. E. & Luggen, M. E. Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly. Lupus 28, 51\u201358 (2019).","journal-title":"Lupus"},{"key":"1163_CR145","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000580","volume":"8","author":"S Raghunath","year":"2021","unstructured":"Raghunath, S., Glikmann-Johnston, Y., Morand, E., Stout, J. C. & Hoi, A. Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE. Lupus Sci. Med. 8, e000580 (2021).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR146","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1177\/09612033211061062","volume":"30","author":"E Papastefanakis","year":"2021","unstructured":"Papastefanakis, E. et al. Screening for cognitive impairment in systemic lupus erythematosus: application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample. Lupus 30, 2237\u20132247 (2021).","journal-title":"Lupus"},{"key":"1163_CR147","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1177\/09612033221132237","volume":"31","author":"XR Lim","year":"2022","unstructured":"Lim, X. R. et al. Montreal cognitive assessment as a screening instrument for cognitive impairment in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 31, 1759\u20131769 (2022).","journal-title":"Lupus"},{"key":"1163_CR148","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/acr.24971","volume":"75","author":"OE Tayer-Shifman","year":"2023","unstructured":"Tayer-Shifman, O. E. et al. Assessing the utility of the Montreal Cognitive Assessment in screening for cognitive impairment in patients with systemic lupus erythematosus. Arthritis Care Res. 75, 569\u2013577 (2023).","journal-title":"Arthritis Care Res."},{"key":"1163_CR149","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/ard.53.5.298","volume":"53","author":"EM Hay","year":"1994","unstructured":"Hay, E. M. et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann. Rheum. Dis. 53, 298\u2013303 (1994).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR150","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/art.1780400825","volume":"40","author":"JG Hanly","year":"1997","unstructured":"Hanly, J. G., Cassell, K. & Fisk, J. D. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum. 40, 1542\u20131543 (1997).","journal-title":"Arthritis Rheum."},{"key":"1163_CR151","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/rheumatology\/41.4.411","volume":"41","author":"K Waterloo","year":"2002","unstructured":"Waterloo, K., Omdal, R., Husby, G. & Mellgren, S. I. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology 41, 411\u2013415 (2002).","journal-title":"Rheumatology"},{"key":"1163_CR152","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/rheumatology\/keac540","volume":"62","author":"C Dobrowolski","year":"2023","unstructured":"Dobrowolski, C. et al. Association of mycophenolate and azathioprine use with cognitive function in systemic lupus. Rheumatology 62, 1860\u20131869 (2023).","journal-title":"Rheumatology"},{"key":"1163_CR153","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semarthrit.2011.02.005","volume":"41","author":"M Petri","year":"2011","unstructured":"Petri, M., Naqibuddin, M., Sampedro, M., Omdal, R. & Carson, K. A. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin. Arthritis Rheum. 41, 194\u2013202 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"1163_CR154","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1084\/jem.20180776","volume":"215","author":"J Nestor","year":"2018","unstructured":"Nestor, J. et al. Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. J. Exp. Med. 215, 2554\u20132566 (2018).","journal-title":"J. Exp. Med."},{"key":"1163_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000923","volume":"10","author":"C Dobrowolski","year":"2023","unstructured":"Dobrowolski, C. et al. Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE. Lupus Sci. Med. 10, e000923 (2023).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR156","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1212\/01.wnl.0000180938.69146.5e","volume":"65","author":"MJ Harrison","year":"2005","unstructured":"Harrison, M. J. et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 65, 1325\u20131327 (2005).","journal-title":"Neurology"},{"key":"1163_CR157","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/ken260","volume":"47","author":"JM Pego-Reigosa","year":"2008","unstructured":"Pego-Reigosa, J. M. & Isenberg, D. A. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology 47, 1498\u20131502 (2008).","journal-title":"Rheumatology"},{"key":"1163_CR158","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/cpt1972135part1694","volume":"13","author":"The Boston Collaborative Drug Surveillance Program.","year":"1972","unstructured":"The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin. Pharmacol. Ther. 13, 694\u2013698 (1972).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1163_CR159","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/art.21539","volume":"54","author":"FB Karassa","year":"2006","unstructured":"Karassa, F. B. et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 54, 312\u2013324 (2006).","journal-title":"Arthritis Rheum."},{"key":"1163_CR160","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.berh.2013.07.010","volume":"27","author":"C Magro-Checa","year":"2013","unstructured":"Magro-Checa, C. et al. Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract. Res. Clin. Rheumatol. 27, 405\u2013424 (2013).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1163_CR161","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1177\/0961203319886103","volume":"28","author":"JN Williams","year":"2019","unstructured":"Williams, J. N. et al. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus 28, 1656\u20131662 (2019).","journal-title":"Lupus"},{"key":"1163_CR162","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/09612033231151600","volume":"32","author":"Y Hasegawa","year":"2023","unstructured":"Hasegawa, Y. et al. The pathogenic role of lupus-specific autoantibodies and Interleukin-6 on demyelination of the brainstem and spinal cord in systemic lupus erythematosus. Lupus 32, 401\u2013410 (2023).","journal-title":"Lupus"},{"key":"1163_CR163","doi-asserted-by":"publisher","first-page":"898049","DOI":"10.3389\/fphar.2022.898049","volume":"13","author":"DK Karathanasis","year":"2022","unstructured":"Karathanasis, D. K. et al. Differentiating central nervous system demyelinating disorders: the role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. Front. Pharmacol. 13, 898049 (2022).","journal-title":"Front. Pharmacol."},{"key":"1163_CR164","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/biomedicines11020425","volume":"11","author":"M Swiderek-Matysiak","year":"2023","unstructured":"Swiderek-Matysiak, M. et al. Cerebrospinal fluid biomarkers in differential diagnosis of multiple sclerosis and systemic inflammatory diseases with central nervous system involvement. Biomedicines 11, 425 (2023).","journal-title":"Biomedicines"},{"key":"1163_CR165","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1212\/WNL.0000000000207604","volume":"101","author":"FO Otite","year":"2023","unstructured":"Otite, F. O. et al. Demographic disparities in the incidence, clinical characteristics, and outcome of posterior reversible encephalopathy syndrome in the United States. Neurology 101, e1554\u2013e1559 (2023).","journal-title":"Neurology"},{"key":"1163_CR166","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/acr.22047","volume":"65","author":"CC Lai","year":"2013","unstructured":"Lai, C. C. et al. Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res. 65, 1766\u20131774 (2013).","journal-title":"Arthritis Care Res."},{"key":"1163_CR167","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1177\/0961203319856416","volume":"28","author":"HW Cui","year":"2019","unstructured":"Cui, H. W., Lei, R. Y., Zhang, S. G., Han, L. S. & Zhang, B. A. Clinical features, outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case-control study. Lupus 28, 961\u2013969 (2019).","journal-title":"Lupus"},{"key":"1163_CR168","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10067-017-3892-2","volume":"37","author":"U Damrongpipatkul","year":"2018","unstructured":"Damrongpipatkul, U., Oranratanachai, K., Kasitanon, N., Wuttiplakorn, S. & Louthrenoo, W. Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study. Clin. Rheumatol. 37, 691\u2013702 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1163_CR169","doi-asserted-by":"publisher","first-page":"102739","DOI":"10.1016\/j.autrev.2020.102739","volume":"20","author":"M Valdez-Lopez","year":"2021","unstructured":"Valdez-Lopez, M. et al. Posterior reversible encephalopathy syndrome: a neuropsychiatric manifestation of systemic lupus erythematosus. Autoimmun. Rev. 20, 102739 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR170","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.41070","volume":"72","author":"JG Hanly","year":"2020","unstructured":"Hanly, J. G. et al. Peripheral nervous system disease in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol. 72, 67\u201377 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR171","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0961203319828499","volume":"28","author":"A Bortoluzzi","year":"2019","unstructured":"Bortoluzzi, A. et al. Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus 28, 465\u2013474 (2019).","journal-title":"Lupus"},{"key":"1163_CR172","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.autrev.2017.05.011","volume":"16","author":"P Toledano","year":"2017","unstructured":"Toledano, P. et al. Peripheral nervous system involvement in systemic lupus erythematosus: prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun. Rev. 16, 750\u2013755 (2017).","journal-title":"Autoimmun. Rev."},{"key":"1163_CR173","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1034\/j.1600-0404.2001.103006386.x","volume":"103","author":"R Omdal","year":"2001","unstructured":"Omdal, R. et al. Peripheral neuropathy in systemic lupus erythematosus \u2014 a longitudinal study. Acta Neurol. Scand. 103, 386\u2013391 (2001).","journal-title":"Acta Neurol. Scand."},{"key":"1163_CR174","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.38302","volume":"66","author":"A Oomatia","year":"2014","unstructured":"Oomatia, A., Fang, H., Petri, M. & Birnbaum, J. Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol. 66, 1000\u20131009 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR175","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/archneur.63.3.401","volume":"63","author":"LG Goransson","year":"2006","unstructured":"Goransson, L. G., Tjensvoll, A. B., Herigstad, A., Mellgren, S. I. & Omdal, R. Small-diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch. Neurol. 63, 401\u2013404 (2006).","journal-title":"Arch. Neurol."},{"key":"1163_CR176","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1177\/0961203318783052","volume":"27","author":"PS Matusik","year":"2018","unstructured":"Matusik, P. S., Matusik, P. T. & Stein, P. K. Cardiovascular reflex tests in patients with systemic lupus erythematosus: clinical performance and utility. Lupus 27, 1759\u20131768 (2018).","journal-title":"Lupus"},{"key":"1163_CR177","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000507","volume":"8","author":"AH Zinglersen","year":"2021","unstructured":"Zinglersen, A. H. et al. Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus. Lupus Sci. Med. 8, e000507 (2021).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR178","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064552","volume":"12","author":"AH Zinglersen","year":"2022","unstructured":"Zinglersen, A. H. et al. Vagus nerve stimulation as a novel treatment for systemic lupus erythematous: study protocol for a randomised, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study. BMJ Open\u00a012, e064552 (2022).","journal-title":"BMJ Open"},{"key":"1163_CR179","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1177\/09612033211045050","volume":"30","author":"T Giani","year":"2021","unstructured":"Giani, T. et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus 30, 1955\u20131965 (2021).","journal-title":"Lupus"},{"key":"1163_CR180","doi-asserted-by":"publisher","first-page":"105559","DOI":"10.1016\/j.jbspin.2023.105559","volume":"90","author":"AP Kisaarslan","year":"2023","unstructured":"Kisaarslan, A. P. et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: a multicenter study. Jt Bone Spine 90, 105559 (2023).","journal-title":"Jt Bone Spine"},{"key":"1163_CR181","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10875-022-01407-1","volume":"43","author":"M Labouret","year":"2023","unstructured":"Labouret, M. et al. Juvenile neuropsychiatric systemic lupus erythematosus: identification of novel central neuroinflammation biomarkers. J. Clin. Immunol. 43, 615\u2013624 (2023).","journal-title":"J. Clin. Immunol."},{"key":"1163_CR182","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00296-009-0887-6","volume":"29","author":"S Singh","year":"2009","unstructured":"Singh, S., Gupta, M. K., Ahluwalia, J., Singh, P. & Malhi, P. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol. Int. 29, 1455\u20131461 (2009).","journal-title":"Rheumatol. Int."},{"key":"1163_CR183","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.pediatrneurol.2014.03.027","volume":"51","author":"YC Zuniga Zambrano","year":"2014","unstructured":"Zuniga Zambrano, Y. C. et al. Risk factors for neuropsychiatric manifestations in children with systemic lupus erythematosus: case-control study. Pediatr. Neurol. 51, 403\u2013409 (2014).","journal-title":"Pediatr. Neurol."},{"key":"1163_CR184","doi-asserted-by":"publisher","first-page":"2548142","DOI":"10.1155\/2018\/2548142","volume":"2018","author":"MA Khajezadeh","year":"2018","unstructured":"Khajezadeh, M. A. et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. Neurol. Res. Int. 2018, 2548142 (2018).","journal-title":"Neurol. Res. Int."},{"key":"1163_CR185","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/0961203307078971","volume":"16","author":"SM Benseler","year":"2007","unstructured":"Benseler, S. M. & Silverman, E. D. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 16, 564\u2013571 (2007).","journal-title":"Lupus"},{"key":"1163_CR186","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/acr.21835","volume":"65","author":"HI Brunner","year":"2013","unstructured":"Brunner, H. I. et al. Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 65, 372\u2013381 (2013).","journal-title":"Arthritis Care Res."},{"key":"1163_CR187","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/acr.23163","volume":"69","author":"A AlE\u2019ed","year":"2017","unstructured":"AlE\u2019ed, A. et al. Challenges of diagnosing cognitive dysfunction with neuropsychiatric systemic lupus erythematosus in childhood. Arthritis Care Res. 69, 1449\u20131459 (2017).","journal-title":"Arthritis Care Res."},{"key":"1163_CR188","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.3390\/cells11244054","volume":"11","author":"JC de Amorim","year":"2022","unstructured":"de Amorim, J. C. et al. Cognitive performance in patients with systemic lupus erythematosus using the Ped-ANAM. Cells 11, 4054 (2022).","journal-title":"Cells"},{"key":"1163_CR189","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0961203316689145","volume":"26","author":"C Magro-Checa","year":"2017","unstructured":"Magro-Checa, C. et al. Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort. Lupus 26, 543\u2013551 (2017).","journal-title":"Lupus"},{"key":"1163_CR190","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0002-9343(00)00603-3","volume":"109","author":"FB Karassa","year":"2000","unstructured":"Karassa, F. B. et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med. 109, 628\u2013634 (2000).","journal-title":"Am. J. Med."},{"key":"1163_CR191","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000850","volume":"10","author":"RC Monahan","year":"2023","unstructured":"Monahan, R. C. et al. Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study. Lupus Sci. Med. 10, e000850 (2023).","journal-title":"Lupus Sci. Med."},{"key":"1163_CR192","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3899\/jrheum.081133","volume":"36","author":"JG Hanly","year":"2009","unstructured":"Hanly, J. G. et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J. Rheumatol. 36, 1449\u20131459 (2009).","journal-title":"J. Rheumatol."},{"key":"1163_CR193","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/rheumatology\/41.11.1308","volume":"41","author":"A Jonsen","year":"2002","unstructured":"Jonsen, A., Bengtsson, A. A., Nived, O., Ryberg, B. & Sturfelt, G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology 41, 1308\u20131312 (2002).","journal-title":"Rheumatology"},{"key":"1163_CR194","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1177\/09612033211031008","volume":"30","author":"S Mendelsohn","year":"2021","unstructured":"Mendelsohn, S. et al. Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: a systematic review. Lupus 30, 1617\u20131630 (2021).","journal-title":"Lupus"},{"key":"1163_CR195","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/acr.25090","volume":"75","author":"AE Clarke","year":"2023","unstructured":"Clarke, A. E. et al. Assessing the costs of neuropsychiatric disease in the systemic lupus international collaborating clinics cohort using multistate modeling. Arthritis Care Res. 75, 1859\u20131870 (2023).","journal-title":"Arthritis Care Res."},{"key":"1163_CR196","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","volume":"74","author":"R Cervera","year":"2015","unstructured":"Cervera, R. et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 74, 1011\u20131018 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR197","doi-asserted-by":"publisher","first-page":"v52","DOI":"10.1093\/rheumatology\/keaa404","volume":"59","author":"M Govoni","year":"2020","unstructured":"Govoni, M., & Hanly, J. G. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? Rheumatology 59, v52\u2013v62 (2020).","journal-title":"Rheumatology"},{"key":"1163_CR198","doi-asserted-by":"publisher","first-page":"7430780","DOI":"10.1155\/2019\/7430780","volume":"2019","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. Anti-GAPDH autoantibody is associated with increased disease activity and intracranial pressure in systemic lupus erythematosus. J. Immunol. Res. 2019, 7430780 (2019).","journal-title":"J. Immunol. Res."},{"key":"1163_CR199","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3109\/14397595.2015.1123345","volume":"26","author":"Y Yamada","year":"2016","unstructured":"Yamada, Y. et al. Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus. Mod. Rheumatol. 26, 562\u2013568 (2016).","journal-title":"Mod. Rheumatol."},{"key":"1163_CR200","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/art.20156","volume":"50","author":"RC Williams Jr","year":"2004","unstructured":"Williams, R. C. Jr, Sugiura, K. & Tan, E. M. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 50, 1239\u20131247 (2004).","journal-title":"Arthritis Rheum."},{"key":"1163_CR201","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202201496","volume":"5","author":"IA Muslimov","year":"2022","unstructured":"Muslimov, I. A. et al. Autoimmune RNA dysregulation and seizures: therapeutic prospects in neuropsychiatric lupus. Life Sci. Alliance 5, e202201496 (2022).","journal-title":"Life Sci. Alliance"},{"key":"1163_CR202","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clim.2015.01.010","volume":"157","author":"K Ichinose","year":"2015","unstructured":"Ichinose, K. et al. Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. Clin. Immunol. 157, 114\u2013120 (2015).","journal-title":"Clin. Immunol."},{"key":"1163_CR203","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/art.22451","volume":"56","author":"H Fragoso-Loyo","year":"2007","unstructured":"Fragoso-Loyo, H. et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 56, 1242\u20131250 (2007).","journal-title":"Arthritis Rheum."},{"key":"1163_CR204","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s10067-009-1226-8","volume":"28","author":"S Hirohata","year":"2009","unstructured":"Hirohata, S. et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin. Rheumatol. 28, 1319\u20131323 (2009).","journal-title":"Clin. Rheumatol."},{"key":"1163_CR205","first-page":"16658","volume":"8","author":"JB Wang","year":"2015","unstructured":"Wang, J. B. et al. Role of IL-1\u03b2, IL-1, IL-8 and IFN-\u03b3 in pathogenesis of central nervous system neuropsychiatric systemic lupus erythematosus. Int. J. Clin. Exp. Med. 8, 16658\u201316663 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"1163_CR206","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.110983","volume":"39","author":"H Fragoso-Loyo","year":"2012","unstructured":"Fragoso-Loyo, H., Atisha-Fregoso, Y., Nunez-Alvarez, C. A., Llorente, L. & Sanchez-Guerrero, J. Utility of interferon-\u03b1 as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus. J. Rheumatol. 39, 504\u2013509 (2012).","journal-title":"J. Rheumatol."},{"key":"1163_CR207","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3899\/jrheum.100148","volume":"37","author":"H Fragoso-Loyo","year":"2010","unstructured":"Fragoso-Loyo, H., Cabiedes, J., Atisha-Fregoso, Y., Llorente, L. & Sanchez-Guerrero, J. Utility of serum S100B protein for identification of central nervous system involvement in systemic lupus erythematosus. J. Rheumatol. 37, 2280\u20132285 (2010).","journal-title":"J. Rheumatol."},{"key":"1163_CR208","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0961203317691374","volume":"26","author":"AT Lapa","year":"2017","unstructured":"Lapa, A. T. et al. S100B is associated with cognitive impairment in childhood-onset systemic lupus erythematosus patients. Lupus 26, 478\u2013483 (2017).","journal-title":"Lupus"},{"key":"1163_CR209","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/0961203318804899","volume":"27","author":"E Noris-Garcia","year":"2018","unstructured":"Noris-Garcia, E. Peripheral levels of brain-derived neurotrophic factor and S100B in neuropsychiatric systemic lupus erythematosus. Lupus 27, 2041\u20132049 (2018).","journal-title":"Lupus"},{"key":"1163_CR210","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1002\/art.11279","volume":"48","author":"E Trysberg","year":"2003","unstructured":"Trysberg, E., Nylen, K., Rosengren, L. E. & Tarkowski, A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 48, 2881\u20132887 (2003).","journal-title":"Arthritis Rheum."},{"key":"1163_CR211","doi-asserted-by":"publisher","first-page":"339","DOI":"10.33549\/physiolres.934308","volume":"69","author":"V Balajkova","year":"2020","unstructured":"Balajkova, V. et al. Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus? Physiol. Res. 69, 339\u2013346 (2020).","journal-title":"Physiol. Res."},{"key":"1163_CR212","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/0961203315610206","volume":"25","author":"H Fragoso-Loyo","year":"2016","unstructured":"Fragoso-Loyo, H. et al. Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erythematosus. Lupus 25, 364\u2013369 (2016).","journal-title":"Lupus"},{"key":"1163_CR213","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2018.08.005","volume":"96","author":"EV Mike","year":"2019","unstructured":"Mike, E. V. et al. Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. J. Autoimmun. 96, 59\u201373 (2019).","journal-title":"J. Autoimmun."},{"key":"1163_CR214","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/art.42080","volume":"74","author":"K Vanarsa","year":"2022","unstructured":"Vanarsa, K. et al. Aptamer-based screen of neuropsychiatric lupus cerebrospinal fluid reveals potential biomarkers that overlap with the choroid plexus transcriptome. Arthritis Rheumatol. 74, 1223\u20131234 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1163_CR215","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.20045","volume":"50","author":"H Ainiala","year":"2004","unstructured":"Ainiala, H. et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 50, 858\u2013865 (2004).","journal-title":"Arthritis Rheum."},{"key":"1163_CR216","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0961203319861677","volume":"28","author":"J Jia","year":"2019","unstructured":"Jia, J. et al. Cerebral blood flow abnormalities in neuropsychiatric systemic lupus erythematosus. Lupus 28, 1128\u20131133 (2019).","journal-title":"Lupus"},{"key":"1163_CR217","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736\u2013745 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR218","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis, A., Tziolos, N., Bertsias, G. & Boumpas, D. T. Update on the diagnosis and management of systemic lupus erythematosus. Ann. Rheum. Dis. 80, 14\u201325 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1163_CR219","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.40591","volume":"71","author":"J Hanly","year":"2018","unstructured":"Hanly, J. et al. Nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol. 71, 33\u201342 (2018).","journal-title":"Arthritis Rheumatol."}],"updated-by":[{"DOI":"10.1038\/s41584-024-01193-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01163-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01163-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01163-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T10:04:42Z","timestamp":1731492282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01163-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":219,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01163-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"19 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the peer reviewer\u2019s names were misspelt and have now been amended to Chaim Putterman and Mohammed E. Naffaa in the HTML and PDF versions of the article.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41584-024-01193-7","URL":"https:\/\/doi.org\/10.1038\/s41584-024-01193-7","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}